Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the therapy itself caused any type of secondary cancer in the modified T cells, ...

The first-level transcription factors (TFs), SWNs, include SND1, NST1/2, and VND1-7; first and a half-level TFs include SND2-5; the second-level master switches includes MBY46/83. Only genes that have ...

PHILADELPHIA – The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine, researchers ...

Please provide your email address to receive an email when new articles are posted on . Researchers did not observe insertional mutagenesis of CAR-T products among patients who developed secondary ...